Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 7, Issue 9, Pages e2365-e2365
Publisher
Springer Nature
Online
2016-09-08
DOI
10.1038/cddis.2016.271
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
- (2016) Z Xu et al. LEUKEMIA
- Co-operative and Hierarchical Binding of c-FLIP and Caspase-8: A Unified Model Defines How c-FLIP Isoforms Differentially Control Cell Fate
- (2016) Michelle A. Hughes et al. MOLECULAR CELL
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
- (2015) A. Henssen et al. CLINICAL CANCER RESEARCH
- Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?
- (2015) R. VanderMeer et al. Current Oncology
- EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
- (2015) H. Hernando et al. MOLECULAR CANCER THERAPEUTICS
- BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia
- (2015) Jae-Seok Roe et al. MOLECULAR CELL
- Transcriptional plasticity promotes primary and acquired resistance to BET inhibition
- (2015) Philipp Rathert et al. NATURE
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Potential of epigenetic therapies in the management of solid tumors
- (2015) Víctor Manuel Valdespino-Gomez et al. Cancer Management and Research
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells
- (2014) Stuart J. Gallagher et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
- (2014) Yujie Tang et al. NATURE MEDICINE
- BET Bromodomain Inhibition Triggers Apoptosis of NF1-Associated Malignant Peripheral Nerve Sheath Tumors through Bim Induction
- (2014) Amish J. Patel et al. Cell Reports
- X-Linked Inhibitor of Apoptosis Protein – A Critical Death Resistance Regulator and Therapeutic Target for Personalized Cancer Therapy
- (2014) Petra Obexer et al. Frontiers in Oncology
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
- (2013) Warren A. Whyte et al. CELL
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma
- (2013) P. Bandopadhayay et al. CLINICAL CANCER RESEARCH
- Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
- (2013) Anouk Emadali et al. EMBO Molecular Medicine
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response
- (2013) Kristopher A. Sarosiek et al. MOLECULAR CELL
- Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent ‘type I’ mode
- (2013) B Gillissen et al. Cell Death & Disease
- Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
- (2013) J S Riley et al. Cell Death & Disease
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting c-FLIP in cancer
- (2010) Sarah Shirley et al. CANCER LETTERS
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started